Figure 4.

Effects of lamivudine vs control (placebo or no intervention) on interruption of hepatitis B virus mother-to-child transmission as indicated by serum hepatitis B surface antigen or hepatitis B virus DNA of infants 6-12 mo after birth. Vertical line indicates no difference between compared treatment. Horizontal lines show 95% CIs. Squares indicate point estimates, and the size of the squares indicates the weight of each study in the meta-analysis. HBsAg: Hepatitis B surface antigen; M-H random: Mantel-Haenszel random-effects model; CI: Confidence interval; HBV: Hepatitis B virus; RR: Risk ratio.